These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37086925)

  • 21. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
    Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
    Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
    Brand LJ; Olson ME; Ravindranathan P; Guo H; Kempema AM; Andrews TE; Chen X; Raj GV; Harki DA; Dehm SM
    Oncotarget; 2015 Feb; 6(6):3811-24. PubMed ID: 25669987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
    Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
    J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 2,4-D and DCP on the DHT-induced androgenic action in human prostate cancer cells.
    Kim HJ; Park YI; Dong MS
    Toxicol Sci; 2005 Nov; 88(1):52-9. PubMed ID: 16107550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.
    Susa T; Ikaga R; Kajitani T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
    J Cell Physiol; 2015 Jul; 230(7):1594-606. PubMed ID: 25536295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
    Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
    Hess-Wilson JK; Webb SL; Daly HK; Leung YK; Boldison J; Comstock CE; Sartor MA; Ho SM; Knudsen KE
    Environ Health Perspect; 2007 Nov; 115(11):1646-53. PubMed ID: 18007998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dihydrotestosterone increases the risk of bladder cancer in men.
    Gil D; Zarzycka M; Dulińska-Litewka J; Ciołczyk-Wierzbicka D; Lekka M; Laidler P
    Hum Cell; 2019 Jul; 32(3):379-389. PubMed ID: 31119584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of Bisphenol A on androgen receptor antagonism.
    Huang X; Cang X; Liu J
    Toxicol In Vitro; 2019 Dec; 61():104621. PubMed ID: 31415812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
    Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
    [No Abstract]   [Full Text] [Related]  

  • 35. SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.
    Thomas R; Sharifi N
    Mol Cancer Ther; 2012 Jan; 11(1):87-97. PubMed ID: 22172488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
    Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
    Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
    Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.
    Hodgson MC; Astapova I; Cheng S; Lee LJ; Verhoeven MC; Choi E; Balk SP; Hollenberg AN
    J Biol Chem; 2005 Feb; 280(8):6511-9. PubMed ID: 15598662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
    Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
    Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.